| 產品編號 | bs-10428R |
| 英文名稱 | Rabbit Anti-C2a antibody |
| 中文名稱 | 補體C2a鏈多肽抗體 |
| 別 名 | Complement C2a fragment; C2; C2 protein; C3/C5 convertase; CO 2; CO2; complement C2; Complement component 2; complement component C2; DKFZp779M0311; OTTHUMP00000062690; CO2_HUMAN. |
 |
Specific References (1) | bs-10428R has been referenced in 1 publications.
[IF=4.55] Caine, Jennifer A., et al. "Borrelia burgdorferi outer surface protein C (OspC) binds complement component C4b and confers bloodstream survival." Cellular Microbiology (2017). IF(ICC) ; Human.
|
| 研究領域 | 心血管 免疫學 糖蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human |
| 產品應用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 56kDa |
| 細胞定位 | 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human C2a: 401-500/752 |
| 亞 型 | |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
Component C2 is a serum glycoprotein that functions as part of the classical pathway of the complement system. Activated C1 cleaves C2 into C2a and C2b. The serine proteinase C2a then combines with complement factor 4b to create the C3 or C5 convertase. Deficiency of C2 has been reported to associated with certain autoimmune diseases and SNPs in this gene have been associated with altered susceptibility to age-related macular degeneration. This gene localizes within the class III region of the MHC on the short arm of chromosome 6. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described in publications but their full-length sequence has not been determined.[provided by RefSeq, Mar 2009]. Function: Component C2 which is part of the classical pathway ofthe complement system is cleaved by activated factor C1 into twofragments: C2b and C2a. C2a, a serine protease, then combines withcomplement factor 4b to generate the C3 or C5 convertase. Subunit: C2a interacts with Schistosoma haematobium TOR (viaN-terminal extracellular domain). This results in inhibition of theclassical and lectin pathway of complement activation, probably dueto interference with binding of C2a to C4b such that C3 convertasecannot be formed. This infers resistance to complement-mediatedcell lysis, allowing parasite survival and infection. Subcellular Location: Secreted. DISEASE: Defects in C2 are the cause of complement component 2deficiency (C2D) [MIM:217000]. A deficiency of the complementclassical pathway associated with the development of autoimmunedisorders, mainly systemic lupus erythematosus. Skin and jointmanifestations are common and renal disease is relatively rare.Patients with complement component 2 deficiency are also reportedto have recurrent or invasive infections. Similarity: Belongs to the peptidase S1 family. Contains 1 peptidase S1 domain. Contains 3 Sushi (CCP/SCR) domains. Contains 1 VWFA domain. SWISS: P06681 Gene ID: 717 Database links: Entrez Gene: 717 Human Omim: 217000 Human SwissProt: P06681 Human Unigene: 408903 Human |
| 產品圖片 |
Paraformaldehyde-fixed, paraffin embedded (human heart); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Incubation with (C2a) Polyclonal Antibody, Unconjugated (bs-10428R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
